vendredi 4 mars 2016

Onco Actu du 4 mars 2016


1. Biologie

Piecing together the mosaic: how genetic research is revealing new connections [Cancer Research UK]


2. Etiologie

High Glycemic Index Associated With Increased Risk of Lung Cancer [AACR]

Genital talc boosts ovarian cancer risk in study [Reuters]

2.6 Etiologie - Environnement

EU seen approving weed-killer ingredient glyphosate amid cancer row [Reuters]

3.4.1 Chimioprévention - aspirine

Aspirin found to reduce overall cancer risk [Harvard Gazette]

Taking two aspirin a week could protect against cancer [The Telegraph]

Prolonged aspirin use tied to reduced colon cancer risk [Reuters]

4.12 Biopsies liquides

Digital Pathology at Scale: Epic Sciences Takes CTC Technology to the Next Level [Mendelspod]


5. Traitements

Progress in targeting tumour cells, avoiding healthy cells [PHG Foundation]

5.12 Immunothérapies

New immunotherapy discovery could give treatments the precision they need [Cancer Research UK]

Where Cancer Immunotherapy Works (and Doesn’t) [In the Pipeline]

Cancer study identifies likely responders to immune therapy [STAT]

Tumours contain the seeds of their own destruction [Cancer Research UK]

The Most Promising Cancer Therapy in Decades Is About to Get Better [The Atlantic]

This $150,000 Cancer Treatment Saved a Pharma Company [Bloomberg]

Scientists find 'Achilles' heel' of cancer offering hope for most deadly cases [The Telegraph]

Genetics of cancer tumours reveal possible treatment revolution [The Guardian]

5.12.2 Immunothérapies - CAR-T

Autolus fundraising now tops $105M for next-gen CAR-T work [FierceBiotech]

Advances in Immunotherapy: Tackling CAR T-cell Therapy Resistance [CANCER RESEARCH Catalyst]

5.2 Pharma

Stealthy MIT Spinout Ribon, Led by a Sanofi Vet, Takes Aim at Cancer [Xconomy]

5.2.1 Pharma - Partenariats

Pfizer, Merck KGaA partner PD-L1 drug with Verastem's failed cancer drug [FierceBiotech]

Merck, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer [Pfizer]

Merck announces drug discovery collaboration with European Molecular Biology Laboratory [Pharmafile]

5.3 Traitements - FDA, EMA,...

Guidance for the publication of clinical data [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

FDA approves new indication for FASLODEX® (fulvestrant) [AstraZeneca]